Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062337 | 0.74 | FAAH (0.33) | TSHRMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL5767016 | 0.70 | MMP8 (0.39) | TSHRRAB9AMAPTALDH1A1KMT2A | |
| SCHEMBL7062957 | 0.69 | CYP2A6 (0.50) | KMT2AMEN1 | |
| SCHEMBL24060791 | 0.69 | CHRM2 (0.48) | MAPTALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL7063618 | 0.68 | HDAC3 (0.35) | RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6762362 | 0.68 | RIPK1 (0.37) | ALDH1A1KMT2AMEN1KDM4EPOLB | |
| SCHEMBL843371 | 0.66 | CHRM2 (0.69) | TSHRALDH1A1KMT2AMEN1CHRM2 | |
| SCHEMBL5767277 | 0.66 | ESR1 (0.41) | — | |
| SCHEMBL216619 | 0.66 | HSD17B10 (0.60) | TSHRRAB9AMAPTALDH1A1KMT2A | |
| SCHEMBL1303144 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | ASTRAZENECA AB (SE) | 2003-08-28 | — | — | US | disclosed |
| EP-1248621-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001047523-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162783-A1 | Method and composition for the treatment of pain | OPRK1, OPRD1, ACHE | TSHR 2873/4885RAB9A 3496/4885MAPT 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.